id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-4964-0009,FDA,FDA-2019-D-4964,Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Draft Guidance for Industry; Availability; Extension of Comment Period,Notice,Extension of Comment Period,2020-01-27T05:00:00Z,2020,1,2020-01-27T05:00:00Z,,2020-07-28T15:21:43Z,2020-01322,0,0,09000064842f5943
FDA-2019-D-4964-0008,FDA,FDA-2019-D-4964,Request for Extension from Pharmaceutical Research and Manufacturers of America (PhRMA),Other,Request for Extension,2020-01-13T05:00:00Z,2020,1,2020-01-13T05:00:00Z,,2020-01-13T21:27:59Z,,0,0,090000648429340e